REDEFINING TREATMENT for people with PNH LEARN MORE 1 2 3 With courageous science, creativity, and compassion, we are committed to delivering therapies for people with complement-driven diseases. ABOUT US Latest news November 12, 2021 Apellis Reiterates Plans to Submit a New Drug Application in the First Half of 2022 for Pegcetacoplan for Geographic Atrophy Following FDA Feedback November 10, 2021 Apellis Announces Three Oral Presentations of the Phase 3 DERBY and OAKS Data in Geographic Atrophy (GA) to be Highlighted at the AAO Annual Meeting November 8, 2021 Apellis Pharmaceuticals Reports Third Quarter 2021 Financial Results NEWSROOM @ApellisPharma For a 3rd year in a row, #Apellis partnered with @OpenTableMA to make the holidays a little brighter for those struggling with food insecurity. Together, Apellucians exceeded our donation goal, ensuring that families across MA had food on the table this #Thanksgiving. #WeCare At the heart of our company is the belief that exceptional science and compassion are not mutually exclusive. FOR PATIENTS Our groundbreaking science targeting C3 offers the potential to provide comprehensive control of complement, a part of the immune system OUR SCIENCE We aim to transform treatment across a broad range of debilitating diseases driven by complement PIPELINE WE REPLACE IMPOSSIBLE WITH HOW We challenge conventional thinking and always question if there's a better way. JOIN US ©2021 Apellis Pharmaceuticals, Inc. All rights reserved. | Privacy Policy | Product Patents This website is intended for residents of the U.S.

Skip to main navigation Loading... Investors & Media Home / Investors & Media / Investor FAQs Investor FAQs Show All When was Apellis founded? Incorporated in Delaware on September 25, 2009 Started operations in 2009 Where is Apellis stock listed and what is the ticker symbol? Where is Apellis located? When is Apellis’ fiscal year end? Can I buy stock directly from Apellis? How can I get a copy of Apellis Annual Report or any other investor materials? Who are Apellis’ auditors? Who is Apellis’ transfer agent and how does a registered shareholder contact the agent regarding account information? Who is Apellis’ outside legal counsel? Who should I contact if I want to learn more about Apellis? How can I sign up to receive news releases & other company information? © Apellis Pharmaceuticals 2021. | Privacy Policy This website is intended for residents of the U.S.

About Us Home / About Us / Board of Directors Board of Directors GERALD CHAN, SD CHAIRMAN SINCLAIR DUNLOP, MBA DIRECTOR STEPHANIE MONAGHAN O’BRIEN, JD DIRECTOR PAUL FONTEYNE, MS, MBA DIRECTOR CEDRIC FRANCOIS, MD, PHD CO-FOUNDER & CHIEF EXECUTIVE OFFICER/PRESIDENT ALEC MACHIELS, JD, MBA CO-FOUNDER ©2021 Apellis Pharmaceuticals, Inc. All rights reserved. | Privacy Policy | Product Patents This website is intended for residents of the U.S.